Xinglou Chengqi Decoction

Xinglou Chengqi Decoction is a traditional Chinese medicine (TCM) formula composed of three botanical drugs and one inorganic drug. It was originally developed as "Huatan Tongfu" decoction in 1986 and later renamed to its current name for clinical use in the treatment of acute stroke, particularly ischemic stroke complicated with Tanre Fushi (TRFS) syndrome[5]. The decoction contains a complex mixture of chemical constituents—197 compounds have been identified or tentatively characterized—with 22 key active ingredients such as luteolin, apigenin, and chrysoeriol shown to exhibit anti-neuroinflammatory effects[5]. Mechanistically, these components are believed to act on multiple targets involved in inflammation and immune-related pathways. Preclinical studies indicate that Xinglou Chengqi Decoction can improve neurological function after experimental stroke by modulating the gut microbiota and regulating neuroinflammation[3][6]. Clinical network meta-analyses suggest it may be effective for improving outcomes in patients with ischemic stroke when compared to standard care or other TCM formulas[4].

Brand names

Xinglouchengqi granules

Other names

XLCQDXLCQ decoctionXinglou Chengqi Tang